ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / TRAW / insiders
APUS (37) AZTR (33) XBIO (32) CANF (25) ⌘ Pro Terminal β†’

Traws Pharma Inc. (TRAW) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.30 +1.45% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.30

Traws Pharma Inc. (TRAW) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $4.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TRAW Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is TRAW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Traws Pharma Inc. (NASDAQ: TRAW) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.30 (+1.45% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TRAW ranks #782 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does TRAW compare to APUS and AZTR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRAW carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -6.2%, cap $4.6M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, TRAW leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TRAW?
β–Ό

Per TRAW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130598), Traws Pharma Inc. generated $2.8M in revenue (+1134.5% YoY), $9.2M in net income, and -$18.2M in free cash flow against $10.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.30 (+0.07%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (4)Whales (5)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.3% Base Target
$3 Bull$0 Base$0 Bear
πŸ“¬ FREE TRAW RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for TRAW)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY TRAW SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 25.8 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
39
Grade E$0.41-7.3% Next Q
Q2 (-2Q)
36
Grade E$0.38-2.6% Next Q
Q3 (-1Q)
34
Grade E$0.37-18.9% Next Q
Current
31
Grade E$0.30-9.4% Hist 90D Ξ±
Trajectory: E (39) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a TRAW Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While TRAW currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.48) and Max Pain ($0.32) forces dealer call-delta covering toward $3.39.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRAWβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œTRAW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

TRAW Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TRAW)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TRAW. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRAW)

  • βœ“Walkthrough of TRAW's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
TRAW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.13%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.30H $0.30L $0.30C $0.30VOL 199.5K
RES: $0.79SUP: $0.28SMA50: $0.48SMA200: $1.15
$3.44$2.58$1.73$0.88$0.03RES $0.79SUP $0.28$0.302026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRAW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ TRAW Butterfly Map β†’ + Track TRAW β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +1134.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TRAW today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for TRAW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TRAW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRAW)

Health Care Rank #782 of 1015 βš”οΈ APUS vs TRAW Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (TRAW vs. APUS, AZTR, XBIO, CANF)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Traws Pharma Inc. (TRAW) ranks #782 by composite RQD confidence (31/100, grade E) and #952 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, TRAW leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and β€” gross margin. APUS currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with TRAW at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TRAW ACTIVE
Traws Pharma Inc.
E 31/100 β€” β€” -35.0% +1.45% $4.5M Benchmark Subject
APUS
Apimeds Pharmaceuticals US Inc.
D- 37/100 β€” β€” -6.2% -3.99% $4.6M /apus-vs-traw β†’
AZTR
Azitra Inc
E 33/100 β€” β€” -35.0% +8.72% $4.7M /aztr-vs-traw β†’
XBIO
Xenetic Biosciences Inc.
E 32/100 β€” β€” -30.3% +0.49% $4.8M /xbio-vs-traw β†’
CANF
Can-Fite Biopharma Ltd each representing two (2)
E 25/100 β€” β€” -35.0% +0.62% $4.9M /canf-vs-traw β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001130598 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Traws Pharma Inc. (TRAW) reported GAAP revenue of $2.8M (+1134.5% vs. FY2024 revenue of $226.0K , and +1134.5% cumulative change since FY2023) , GAAP net income of $9.2M, operating cash flow of -$18.2M, and free cash flow of -$18.2M (+39.0% YoY). On the balance sheet, TRAW closed FY2025 with $10.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.8M $9.2M -$18.2M -$18.2M $10.6M β€”
FY2024 (FY) 2024-12-31 $226.0K -$166.5M -$29.8M -$29.8M $25.0M β€”
FY2023 (FY) 2023-12-31 $226.0K -$18.9M -$17.9M -$17.9M β€” β€”

3. TRAW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRAW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Traws Pharma Inc. (NASDAQ: TRAW) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.30 (+1.45% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TRAW ranks #782 in composite RQD confidence.

How does TRAW compare to APUS and AZTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRAW carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -6.2%, cap $4.6M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, TRAW leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRAW?

Per TRAW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130598), Traws Pharma Inc. generated $2.8M in revenue (+1134.5% YoY), $9.2M in net income, and -$18.2M in free cash flow against $10.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRAW trading relative to its 50-day, 200-day, and 52-week technical levels?

TRAW last traded at $0.30 (+1.45% on volume of 70,373 shares), positioning the stock -37.50% below its 50-day simple moving average ($0.48) and -73.91% below its 200-day simple moving average ($1.15). Across its 52-week range of $0.29 to $3.23, TRAW sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.34).

Direct Sub-Reports: TRAW RQD Cockpit TRAW 12M Forecast TRAW Earnings & Move TRAW Dividends & DRIP TRAW Insiders & 13F TRAW Whale Options TRAW Profit Sankey TRAW News & Why
ROARABLE RATING BRIEF β€’ RQD 31/100 (E) βœ“ SEC XBRL & RQD VERIFIED

TRAW β€” Traws Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Traws Pharma Inc. (TRAW) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.30 (+1.45% 1D, market capitalization $4.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Traws Pharma Inc. (TRAW) is listed on NASDAQ and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry,. The profile describes the company as a Health Care issuer with a market capitalization of $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Traws Pharma Inc. (TRAW) reported $2.8M in annual revenue (up from $226.0K in FY2024, +1134.5% YoY) and $9.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($226.0K revenue, -$18.9M net income) through FY2025, TRAW scaled operating cash flow to -$18.2M and free cash flow to -$18.2M, backed by $10.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.29 – $3.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE and butterfly_links is empty, so no upstream or downstream dependencies are mapped. Sector correlations and 2nd-order bottlenecks are β€” The only sector context is the Health Care / Pharmaceutical Preparations classification.

  • Key Question #1: Can TRAW sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.8M and free cash flow of -$18.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TRAW's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TRAW Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Traws Pharma Inc. (TRAW) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to TRAW Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TRAW Bull vs. Bear Conversation Board β€” What's Your Call at $0.30?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRAW 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TRAW:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $0.35 (+16.7%)
πŸ“Œ Pinned Debate

A $50 million equity financing facility could fund operations if the company converts it into sustained cash generation.

Here is why I am bullish on TRAW here at $0.30: A $50 million equity financing facility could fund operations if the company converts it into sustained cash generation.. Compare TRAW's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.28 are getting bought.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” TRAW's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.23 (-23.3%)
Spot @ $0.30

ROIC of -35%, FCF yield of 0%, and a 3/9 Piotroski F-Score point to continued cash burn and forensic weakness.

Sitting on the sidelines or leaning short TRAW above $0.30. ROIC of -35%, FCF yield of 0%, and a 3/9 Piotroski F-Score point to continued cash burn and forensic weakness.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $3.23.

LIVE TAPE